BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

292 related articles for article (PubMed ID: 31772119)

  • 21. A Phase I Dose-Escalation Study of Clofarabine in Patients with Relapsed or Refractory Low-Grade or Intermediate-Grade B-Cell or T-Cell Lymphoma.
    Foss FM; Parker T
    Oncologist; 2018 Apr; 23(4):397-e30. PubMed ID: 29438091
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Safety and effectiveness of mogamulizumab in relapsed or refractory CC chemokine receptor 4-positive peripheral T-cell lymphoma and relapsed or refractory cutaneous T-cell lymphoma: A post-marketing surveillance in Japan.
    Ishitsuka K; Yasukawa T; Tsuji Y
    Hematol Oncol; 2024 Jul; 42(4):e3292. PubMed ID: 38847317
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Romidepsin for the Treatment of Peripheral T-Cell Lymphoma.
    Iyer SP; Foss FF
    Oncologist; 2015 Sep; 20(9):1084-91. PubMed ID: 26099743
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A Phase II trial of Belinostat (PXD101) in patients with relapsed or refractory peripheral or cutaneous T-cell lymphoma.
    Foss F; Advani R; Duvic M; Hymes KB; Intragumtornchai T; Lekhakula A; Shpilberg O; Lerner A; Belt RJ; Jacobsen ED; Laurent G; Ben-Yehuda D; Beylot-Barry M; Hillen U; Knoblauch P; Bhat G; Chawla S; Allen LF; Pohlman B
    Br J Haematol; 2015 Mar; 168(6):811-9. PubMed ID: 25404094
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A phase 1 study of bortezomib and romidepsin in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma, indolent B-cell lymphoma, peripheral T-cell lymphoma, or cutaneous T-cell lymphoma.
    Holkova B; Yazbeck V; Kmieciak M; Bose P; Ma S; Kimball A; Tombes MB; Shrader E; Wan W; Weir-Wiggins C; Singh A; Hogan KT; Conine S; Sankala H; Roberts JD; Shea TC; Grant S
    Leuk Lymphoma; 2017 Jun; 58(6):1349-1357. PubMed ID: 28103725
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Responses to romidepsin in patients with cutaneous T-cell lymphoma and prior treatment with systemic chemotherapy.
    Duvic M; Bates SE; Piekarz R; Eisch R; Kim YH; Lerner A; Robak T; Samtsov A; Becker JC; McCulloch W; Waksman J; Whittaker S
    Leuk Lymphoma; 2018 Apr; 59(4):880-887. PubMed ID: 28853310
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical Efficacy of Romidepsin in Tumor Stage and Folliculotropic Mycosis Fungoides.
    Foss F; Duvic M; Lerner A; Waksman J; Whittaker S
    Clin Lymphoma Myeloma Leuk; 2016 Nov; 16(11):637-643. PubMed ID: 27637428
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Romidepsin-Bendamustine Combination for Relapsed/Refractory T Cell Lymphoma.
    Nachmias B; Shaulov A; Lavie D; Goldschmidt N; Gural A; Saban R; Lebel E; Gatt ME
    Acta Haematol; 2019; 141(4):216-221. PubMed ID: 30943470
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Multicenter phase II study of mogamulizumab (KW-0761), a defucosylated anti-cc chemokine receptor 4 antibody, in patients with relapsed peripheral T-cell lymphoma and cutaneous T-cell lymphoma.
    Ogura M; Ishida T; Hatake K; Taniwaki M; Ando K; Tobinai K; Fujimoto K; Yamamoto K; Miyamoto T; Uike N; Tanimoto M; Tsukasaki K; Ishizawa K; Suzumiya J; Inagaki H; Tamura K; Akinaga S; Tomonaga M; Ueda R
    J Clin Oncol; 2014 Apr; 32(11):1157-63. PubMed ID: 24616310
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Romidepsin and lenalidomide-based regimens have efficacy in relapsed/refractory lymphoma: Combined analysis of two phase I studies with expansion cohorts.
    Mehta-Shah N; Lunning MA; Moskowitz AJ; Boruchov AM; Ruan J; Lynch P; Hamlin PA; Leonard J; Matasar MJ; Myskowski PL; Marzouk E; Nair S; Sholklapper T; Minnal V; Palomba ML; Vredenburgh J; Kumar A; Noy A; Straus DJ; Zelenetz AD; Schoder H; Rademaker J; Schaffer W; Galasso N; Ganesan N; Horwitz SM
    Am J Hematol; 2021 Oct; 96(10):1211-1222. PubMed ID: 34251048
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Romidepsin: a histone deacetylase inhibitor for refractory cutaneous T-cell lymphoma.
    Kim M; Thompson LA; Wenger SD; O'Bryant CL
    Ann Pharmacother; 2012 Oct; 46(10):1340-8. PubMed ID: 22968522
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Activity of the PI3K-δ,γ inhibitor duvelisib in a phase 1 trial and preclinical models of T-cell lymphoma.
    Horwitz SM; Koch R; Porcu P; Oki Y; Moskowitz A; Perez M; Myskowski P; Officer A; Jaffe JD; Morrow SN; Allen K; Douglas M; Stern H; Sweeney J; Kelly P; Kelly V; Aster JC; Weaver D; Foss FM; Weinstock DM
    Blood; 2018 Feb; 131(8):888-898. PubMed ID: 29233821
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Romidepsin in peripheral and cutaneous T-cell lymphoma: mechanistic implications from clinical and correlative data.
    Bates SE; Eisch R; Ling A; Rosing D; Turner M; Pittaluga S; Prince HM; Kirschbaum MH; Allen SL; Zain J; Geskin LJ; Joske D; Popplewell L; Cowen EW; Jaffe ES; Nichols J; Kennedy S; Steinberg SM; Liewehr DJ; Showe LC; Steakley C; Wright J; Fojo T; Litman T; Piekarz RL
    Br J Haematol; 2015 Jul; 170(1):96-109. PubMed ID: 25891346
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Results from a prospective, open-label, phase II trial of bendamustine in refractory or relapsed T-cell lymphomas: the BENTLY trial.
    Damaj G; Gressin R; Bouabdallah K; Cartron G; Choufi B; Gyan E; Banos A; Jaccard A; Park S; Tournilhac O; Schiano-de Collela JM; Voillat L; Joly B; Le Gouill S; Saad A; Cony-Makhoul P; Vilque JP; Sanhes L; Schmidt-Tanguy A; Bubenheim M; Houot R; Diouf M; Marolleau JP; Béné MC; Martin A; Lamy T
    J Clin Oncol; 2013 Jan; 31(1):104-10. PubMed ID: 23109692
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Phase II multi-institutional trial of the histone deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous T-cell lymphoma.
    Piekarz RL; Frye R; Turner M; Wright JJ; Allen SL; Kirschbaum MH; Zain J; Prince HM; Leonard JP; Geskin LJ; Reeder C; Joske D; Figg WD; Gardner ER; Steinberg SM; Jaffe ES; Stetler-Stevenson M; Lade S; Fojo AT; Bates SE
    J Clin Oncol; 2009 Nov; 27(32):5410-7. PubMed ID: 19826128
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The discovery and development of romidepsin for the treatment of T-cell lymphoma.
    Smolewski P; Robak T
    Expert Opin Drug Discov; 2017 Aug; 12(8):859-873. PubMed ID: 28641053
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Romidepsin: a guide to its clinical use in cutaneous T-cell lymphoma.
    Lyseng-Williamson KA; Yang LP
    Am J Clin Dermatol; 2012 Feb; 13(1):67-71. PubMed ID: 22066664
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Interferon and low doses of methotrexate versus interferon and retinoids in the treatment of refractory/relapsed cutaneous T-cell lymphoma.
    Aviles A; Neri N; Fernandez-Diez J; Silva L; Nambo MJ
    Hematology; 2015 Oct; 20(9):538-42. PubMed ID: 25592781
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Relief of intractable pruritus with romidepsin in patients with cutaneous T-cell lymphoma: A series of four cases.
    Poligone B; Rubio-Gonzalez B; Querfeld C
    Dermatol Ther; 2019 Mar; 32(2):e12804. PubMed ID: 30549384
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Combined oral 5-azacytidine and romidepsin are highly effective in patients with PTCL: a multicenter phase 2 study.
    Falchi L; Ma H; Klein S; Lue JK; Montanari F; Marchi E; Deng C; Kim HA; Rada A; Jacob AT; Kinahan C; Francescone MM; Soderquist CR; Park DC; Bhagat G; Nandakumar R; Menezes D; Scotto L; Sokol L; Shustov AR; O'Connor OA
    Blood; 2021 Apr; 137(16):2161-2170. PubMed ID: 33171487
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.